Recon: Eli Lilly selects Virginia as $5B API site; CSL invests $117M in VarmX coagulation drug

• Hill staff gets briefed on implications of Trump’s drug pricing plan (STAT)
• Lilly weight-loss pill could be FDA-approved by year-end (Reuters)
• GOP Unveils Bill to Avert Shutdown, Daring Democrats to Oppose (Bloomberg)
• CRLs Today, (Potential) Lawsuits Tomorrow (FDA Law Blog)
• FDA Letters Flag Oprah Video, Morgan Freeman Ad in Crackdown (Bloomberg)

• UK must spend more on medicines, minister says, as Big Pharma cuts investment (Reuters)
• Ark, Atom file to go public in Hong Kong; Aptevo’s stock rallies on AML data (Endpoints)
• Italy’s Chiesi Raises Annual Guidance on Drug Sales Growth (Bloomberg)
• Medical-Device Maker Mindray Picks Huatai, JPMorgan for Hong Kong Listing (Bloomberg)
• Chinese Biotech Stock’s 4,500% Surge Sparks Fear of Market Froth (Bloomberg)
• EU’s Draft GMP Guideline Signals Major Cultural Shift In Pharma Quality Compliance (Pink Sheet)
• First-In-Class Bronchiectasis Treatment Among 14 Drugs Awaiting EMA Verdict (Pink Sheet)
• Australia's CSL invests $117 million for VarmX acquisition option, coagulation treatment (Reuters)

• Critics call on Sarepta to show how it’s measuring gene therapy’s performance (STAT)
• Novo Nordisk eyes broader role for its obesity drugs from sleep apnea to knees (Reuters)
• Novo Nordisk Overhauls Senior Job Titles in Latest Shake-Up (Bloomberg)
• Eli Lilly picks Virginia for $5B API site as part of $27B US pledge (Endpoints)
• Former CinCor executives return with new ‘hub-and-spoke’ company, old Sanofi drug (Endpoints)
• Genmab ends work on ADC from $1.8B acquisition of ProfoundBio (Endpoints)
• Dualitas gets $65M in Series A to develop bispecifics for immunology (Endpoints)

• Amazon ropes in Fay to offer dietitian services on telehealth platform (Reuters)
• Exclusive: Fred Hutch duo's startup launches with $10M to build AI generative genomics models (Endpoints)
• How three companies are using foundation models in radiology (MedTech Dive)
• Insulet names new CFO; Dexcom CEO on leave (MedTech Dive)

• Tyson to end use of high fructose corn syrup (Food Dive)
• Grocery inflation hits a 2-year high (Food Dive)

• The marijuana rescheduling debate is missing the point, experts say (STAT)
• I’m a former CDC director. I’m deeply concerned about the future of vaccines in the U.S. (STAT)
• Tylenol in pregnancy: A question of safety or control? (STAT)
• At Wellness Resorts, Ozempic Becomes Part of the Treatment Menu (Bloomberg)
• A Cheap Way to Protect Cancer Patients From Covid (Bloomberg)
• Do Policy, Clinical Data, Ocaliva Exit Lend Zydus Helping Hands? (Pink Sheet)